retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA Retatrutide: Eli Lilly's GLP-1 Triple

Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk

Transform your wellness journey - try GLP-1 Pro Probiotic Blend+ today!

A large global retrospective cohort study (n=331,863 matched patients

Coronary artery disease (CAD)cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteriesis responsible for disa...

Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

India stands tall as the worlds pharmacy now poised to lead the GLP-1 revolution